Navigating the complex landscape of legal acquisition for controlled substances, specifically Schedule I drugs, represents a particularly specialized area for licensed Québécois institutions—typically research facilities—and demands meticulous adherence to stringent regulations. Such process goes far beyond standard vendor selection, encompas